Electrophysiological Effects of Late PCI After MI

Cardiovascular Diseases Clinical Trial

Official title:

Electrophysiological Effects of Late PCI (OAT-EP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00119847
• Other study ID #: 221
• Secondary ID: R01HL072906
• Status: Completed
• Phase: N/A
• Start date: September 2002
• Est. completion date: December 2006

Study information

• Verified date: May 2022
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if opening blocked arteries with heart balloons and stents prevents heart rhythm problems in individuals 3 to 28 days after a heart attack.

Description:

BACKGROUND:

There is now unequivocal evidence that early coronary reperfusion using either thrombolytics or primary angioplasty results in a long-term mortality reduction among individuals who have had a heart attack. The benefit of early reperfusion (less than 6 hours after the heart attack) was initially attributed to myocardial salvage and the resultant preservation of left ventricular function. However, it is now known that the survival benefit associated with thrombolytic therapy is not consistently associated with a major improvement in left ventricular ejection fraction (LVEF). These observations led to the formulation of the "late open artery hypothesis," which suggests that clinical outcomes can potentially be improved by late reperfusion after a heart attack. Observational clinical studies have suggested that late patency of the infarct-related artery (IRA) after thrombolysis is associated with a survival benefit that is independent of LVEF and therefore cannot be solely explained by salvage of myocardium. Definitive proof of the late open artery hypothesis is currently lacking, however, because previous studies that have evaluated late percutaneous transluminal coronary angioplasty (PTCA) of occluded IRAs after a heart attack have produced conflicting results.

These findings led to the organization of the Occluded Artery Trial (OAT), an international, NHLBI-funded, randomized trial of 2,200 participants. OAT is testing the hypothesis that mechanical reperfusion of an occluded IRA with PTCA and percutaneous coronary intervention (PCI) 3 to 28 days after a heart attack in high-risk individuals will reduce mortality, recurrent heart attacks, and hospitalization for class IV congestive heart failure. Enhancement of electrical stability is one of the major mechanisms that has been proposed to explain the association of an open IRA with an improved prognosis independent of myocardial salvage.

DESIGN NARRATIVE:

This study is an ancillary study of OAT. It will characterize the effects of late PCI of occluded IRAs on the most important and clinically relevant noninvasive markers of vulnerability to malignant ventricular arrhythmias: heart rate variability, T wave variability, and signal-averaged electrocardiography. These analyses will be performed in 300 participants at baseline, 30 days, and 1 year following a heart attack in order to determine the effects of late PCI on the autonomic nervous system, ventricular repolarization, and ventricular conduction abnormalities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: December 2006
• Est. primary completion date: December 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Has experienced a heart attack 3 to 28 days prior to study entry

• Persistently occluded IRA defined as either: 1) Thrombolysis in Myocardial Infarction (TIMI) 0, with no flow beyond the site of occlusion; or 2) TIMI 1, with penetration of dye beyond the site of occlusion without dye reaching the distal vessel

• LVEF less than 50% or proximal occlusion in a large vessel

• Normal sinus rhythm

• QRS duration less than 120 ms

• Able to return for follow-up assessment of arrhythmia markers one month and one year after study entry

Exclusion Criteria:

• Has a clinical indication for revascularization (post-heart attack angina at rest; significant inducible ischemia; or significant left main or triple vessel disease requiring PTCA or CABG)

• Current serious illness or condition that limits 3-year survival

• Severe valvular disease

• Chronic total occlusion

• New York Heart Association Class III-IV congestive heart failure

• Prior left ventricular aneurysm in the recent heart attack location

• Is a poor candidate for PTCA/stent on the basis of angiographic or clinical criteria

• Cannot medically survive anticoagulation during PTCA/stent or antiplatelet therapy after stent

• Pregnant

Related Conditions & MeSH terms

• Arrhythmia
• Cardiovascular Diseases
• Coronary Disease
• Heart Diseases
• Infarction
• Myocardial Infarction
• Ventricular Fibrillation

Intervention

Procedure:
• PCI

Drug:
• Optimal Medical Therapy
Guideline-directed drug therapies after MI

Locations

Country	Name	City	State
United States	Stony Brook University Medical Center	Stony Brook	New York

Sponsors (2)

Lead Sponsor	Collaborator
University of Maryland, Baltimore	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Rashba EJ, Lamas GA, Couderc JP, Hollist SM, Dzavik V, Ruzyllo W, Fridrich V, Buller CE, Forman SA, Kufera JA, Carvalho AC, Hochman JS; OAT-EP Investigators. Electrophysiological effects of late percutaneous coronary intervention for infarct-related coron — View Citation

Rashba EJ. Assessment of ventricular repolarization abnormalities in congenital long QT syndrome. J Cardiovasc Electrophysiol. 2004 May;15(5):557-9. — View Citation

Rashba EJ. Should T-wave alternans testing be used to risk stratify candidates for prophylactic implantable cardioverter-defibrillator therapy? Heart Rhythm. 2005 Mar;2(3):242-4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Short-termed Fractal Scaling Exponent (Alpha 1)	Nonlinear measurement of heart rate variability, change between baseline and 1 year is the primary outcome.	Baseline, one year
Secondary	T-wave Variability	Variability in T wave morphology, change between baseline and one year	Baseline and one year
Secondary	Filtered QRS Duration	Signal-averaged ECG	Baseline and one year